Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GANX Gain Therapeutics	$1.94 -4.4%	$1.94	$0.89 ▼ $3.19	$57.09M	0.17	305,536 shs	94,601 shs
IMUC EOM Pharmaceuticals	$0.11 +23.8%	$0.14	$0.01 ▼ $0.25	$13.31M	0.06	8,653 shs	637 shs
MDCX Medicus Pharma	$4.59 +9.8%	$3.65	$1.80 ▼ $6.00	$61.64M	N/A	52,815 shs	129,890 shs
VICP Vicapsys Life Sciences	$1.77	$1.89	$1.25 ▼ $3.00	$57.30M	-4.03	250 shs	N/A

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GANX Gain Therapeutics	-4.20%	-5.83%	+17.58%	-25.67%	-27.61%
IMUC EOM Pharmaceuticals	+23.76%	+19.68%	-24.86%	-23.49%	-49.90%
MDCX Medicus Pharma	+9.81%	+4.08%	+21.75%	+63.93%	+458,999,900.00%
VICP Vicapsys Life Sciences	0.00%	0.00%	0.00%	-13.66%	+298.65%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GANX Gain Therapeutics	3.0509 of 5 stars	3.6	5.0	0.0	0.0	3.0	0.8	0.6
IMUC EOM Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VICP Vicapsys Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GANX Gain Therapeutics	3.17	Buy	$8.20	322.68% Upside
IMUC EOM Pharmaceuticals	0.00	N/A	N/A	N/A
MDCX Medicus Pharma	3.50	Strong Buy	$17.00	270.37% Upside
VICP Vicapsys Life Sciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest IMUC, MDCX, VICP, and GANX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/8/2025	MDCX Medicus Pharma	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $20.00
4/28/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/21/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/14/2025	MDCX Medicus Pharma	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/14/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
3/28/2025	GANX Gain Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/17/2025	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
3/7/2025	GANX Gain Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Perform ➝ Sector Outperform	$12.00

(Data available from 5/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GANX Gain Therapeutics	$50K	1,141.77	N/A	N/A	$0.97 per share	2.00
IMUC EOM Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A	N/A
VICP Vicapsys Life Sciences	N/A	N/A	N/A	N/A	($0.06) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GANX Gain Therapeutics	-$22.27M	-$0.92	N/A	N/A	N/A	N/A	-203.91%	-128.05%	5/13/2025 (Estimated)
IMUC EOM Pharmaceuticals	-$1.61M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	6/27/2025 (Estimated)
VICP Vicapsys Life Sciences	-$1.18M	-$0.04	N/A	∞	N/A	N/A	N/A	-3,906.36%	N/A

Latest IMUC, MDCX, VICP, and GANX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	GANX Gain Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
3/28/2025	Q4 2024	MDCX Medicus Pharma	-$0.32	-$0.18	+$0.14	-$0.18	N/A	N/A
3/27/2025	Q4 2024	GANX Gain Therapeutics	-$0.18	-$0.11	+$0.07	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A
IMUC EOM Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
VICP Vicapsys Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GANX Gain Therapeutics	0.04	2.99	2.99
IMUC EOM Pharmaceuticals	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A
VICP Vicapsys Life Sciences	N/A	0.03	0.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GANX Gain Therapeutics	11.97%
IMUC EOM Pharmaceuticals	N/A
MDCX Medicus Pharma	N/A
VICP Vicapsys Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
GANX Gain Therapeutics	11.70%
IMUC EOM Pharmaceuticals	3.28%
MDCX Medicus Pharma	N/A
VICP Vicapsys Life Sciences	5.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GANX Gain Therapeutics	20	29.43 million	23.42 million	Optionable
IMUC EOM Pharmaceuticals	3	126.50 million	122.35 million	Not Optionable
MDCX Medicus Pharma	N/A	13.43 million	N/A	N/A
VICP Vicapsys Life Sciences	2	32.37 million	30.44 million	Not Optionable

IMUC, MDCX, VICP, and GANX Headlines

Recent News About These Companies

British Science Week - Teaching Resources

November 6, 2024 | bbc.co.uk

Best term life insurance: Expert-rated in April 2024

April 28, 2024 | usatoday.com

Scanning Electron Microscopy for the Life Sciences

April 20, 2024 | cambridge.org

EY Life Sciences

April 8, 2024 | pmlive.com

Life Science

January 30, 2024 | dmagazine.com

Caris Life Sciences

November 30, 2023 | dmagazine.com

Anavex Life Sciences Corp AVXL

November 4, 2023 | morningstar.com

VICP - Vicapsys Life Sciences, Inc.

August 9, 2023 | finance.yahoo.com

ViCapsys files for Nasdaq uplisting, $8M public offering

July 3, 2023 | msn.com

Life sciences sector to get £650m boost in new Government funding package

June 9, 2023 | aol.co.uk

‘Not Seeing Any Activity At All’: Once-Hot Life Sciences Leasing Market Freezes

April 1, 2023 | bisnow.com

The Science of Life

March 29, 2023 | nature.com

The ultimate list of leaders in life sciences.

March 16, 2023 | statnews.com

Defining life and personhood: What science, philosophy, and religion have to say

March 13, 2023 | kcrw.com

Life Sciences Innovator Category Winner 2023

February 23, 2023 | news-medical.net

Global law firm Goodwin is setting up a Philly tech, startups and life sciences practice

February 21, 2023 | technical.ly

Global Life Science Tools Strategic Business Report 2023: Rapid Growth in Biopharma Industry and Rising Investments in R&D to Boost Market Prospects

February 19, 2023 | benzinga.com

Focused exclusively on life sciences, three top investors set out on their own

January 28, 2023 | statnews.com

Top risks for life sciences sector revealed – report

January 15, 2023 | canadianlawyermag.com

Houston On Track As Future Life Sciences Powerhouse, But Everyone Needs To Mind The Gaps First

January 15, 2023 | bisnow.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUC, MDCX, VICP, and GANX Company Descriptions

Gain Therapeutics NASDAQ:GANX

$1.94 -0.09 (-4.43%)

As of 05/9/2025 04:00 PM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

EOM Pharmaceuticals OTCMKTS:IMUC

$0.11 +0.02 (+23.76%)

As of 05/9/2025 03:14 PM Eastern

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

Medicus Pharma NASDAQ:MDCX

$4.59 +0.41 (+9.81%)

As of 05/9/2025 03:59 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

Vicapsys Life Sciences OTCMKTS:VICP

$1.77 0.00 (0.00%)

As of 05/9/2025

Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time